纳武利尤单抗治疗经治晚期非小细胞肺癌的五年随访:CA209-003研究结果
CA209-003是一项早期I期研究,评估纳武利尤单抗在经治晚期非小细胞肺癌(NSCLC)患者中的长期疗效。全部129例患者的估计5年总生存(OS)率为16%,鳞癌与nonsquamous亚型相似(16% vs 15%)。16例5年生存者中,75%达到部分缓解,75%在末次随访时无疾病进展证据且未接受后续治疗。
要点
- 经治晚期NSCLC患者纳武利尤单抗5年OS率为16%,鳞癌与nonsquamous相近。
- 5年生存者中75%达到部分缓解,56%完成96周最大疗程。
核心结论
- 纳武利尤单抗在部分经治晚期NSCLC患者中可带来长期OS和持久缓解。
- 长期生存者的基线及治疗中特征呈多样性。
研究设计与样本
- 早期I期研究,经治晚期NSCLC患者接受纳武利尤单抗1、3或10 mg/kg每2周,8周为一周期,最长96周。
- 共129例患者纳入分析,从首次给药起用Kaplan-Meier法估计OS。
主要发现
- 全部129例患者的估计5年OS率为16%。
- 鳞癌患者5年OS率为16%,nonsquamous患者为15%。
- 16例5年生存者中88%为目前或既往吸烟者。
- 10例可量化PD-L1表达的5年生存者中,70%基线PD-L1表达≥1%。
- 16例5年生存者中12例(75%)最佳疗效为部分缓解,2例(12%)为疾病稳定,2例(12%)为疾病进展。
关键数值与推荐
- 5年生存者中9例(56%)完成最长96周纳武利尤单抗治疗。
- 5年生存者中4例(25%)因不良事件停药,3例(19%)因疾病进展停药。
临床怎么用
- 经治晚期NSCLC可考虑纳武利尤单抗,部分患者可获得5年以上长期生存。
- 长期生存者特征多样,PD-L1表达、吸烟史和缓解深度可作为参考但非绝对预测因素。
局限性
- 为早期I期研究,样本量有限(N=129),非随机对照设计。
- PD-L1表达数据仅在部分5年生存者中可量化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non-small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I study of nivolumab in this patient population and describe characteristics of 5-year survivors. Patients and Methods Patients with pretreated, advanced NSCLC received nivolumab 1, 3, or 10 mg/kg every 2 weeks in 8-week cycles for up to 96 weeks. OS from the time of first dose was estimated by the Kaplan-Meier method. Results The estimated 5-year OS rate was 16% for all treated patients (N = 129); 5-year OS rates were similar for squamous (16%) and nonsquamous (15%) NSCLC. Of 16 5-year survivors, most (88%) were known current or former smokers. Of 10 5-year survivors with quantifiable PD-1 ligand 1 expression, 70% had ≥ 1% PD-1 ligand 1 expression at baseline. Twelve 5-year survivors (75%) achieved a partial response to nivolumab per Response Evaluation Criteria in Solid Tumors, version 1.0, and two each (12%) had stable disease and progressive disease as best response. Nine 5-year survivors (56%) completed the maximum 96 weeks of nivolumab; four (25%) discontinued owing to adverse events and three (19%) owing to disease progression. As of a November 2016 database lock, 12 5-year survivors (75%) received no subsequent therapy and were without evidence of progressive disease at last follow-up. Conclusions Nivolumab treatment resulted in long-term OS and durable responses in a proportion of patients with pretreated advanced NSCLC. Long-term survivors had diverse baseline and on-treatment characteristics.
引用
- Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018. PMID: 29570421. doi:10.1200/JCO.2017.77.0412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。